Hamal, K. B. et al. Synthesis of the Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitor, 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977, Belzutifan); Efficient Replication of Established Approaches. Tetrahedron Letters 128, 154691 (2023).

Pirnot, M. et al. Manufacturing Process Development for Belzutifan, Part 6: Ensuring Scalability for a Deoxyfluorination Reaction. Org. Process Res. Dev. 26, 551–559 (2022).

Wang, T. et al. Manufacturing Process Development for Belzutifan, Part 5: A Streamlined Fluorination–Dynamic Kinetic Resolution Process. Org. Process Res. Dev. 26, 543–550 (2022).

Chen, Z. et al. Manufacturing Process Development for Belzutifan, Part 3: Completing a Streamlined Through-Process with a Safe and Scalable Oxidation. Org. Process Res. Dev. 26, 525–532 (2022).

Bottecchia, C. et al. Manufacturing Process Development for Belzutifan, Part 2: A Continuous Flow Visible-Light-Induced Benzylic Bromination. Org. Process Res. Dev. 26, 516–524 (2022).

BRUICK, R. K., CHEN, Y. & RUIZ, J. C. F. HIF-2α INHIBITORS FOR TREATING IRON OVERLOAD DISORDERS. (2016).

Wehn, P. M. et al. Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate ( S )-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1 H -inden-4-yl)oxy)-5-fluorobenzonitrile (PT2385). J. Med. Chem. 61, 9691–9721 (2018).

Josey, J. A., Wallace, E. M., Du, X. & GOGGIN, B. Compositions for use in treating pulmonary arterial hypertension. (2016).

Ji, Y. et al. Benzylic Photobromination for the Synthesis of Belzutifan: Elucidation of Reaction Mechanisms Using In Situ LED-NMR. J. Org. Chem. 87, 2055–2062 (2022).

薛晓纤 et al. 一种Belzutifan的中间体的制备方法. (2023).

Yang, F., Yu, N., CHI, J., He, F. & Tao, W. 6-oxo-1,6-dihydropyridazine derivative, preparation method therefor and medical use thereof. (2021).

Xu, R. et al. 3-[(1 S ,2 S ,3 R )-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma. J. Med. Chem. 62, 6876–6893 (2019).